Related by context. All words. (Click for frequent words.) 69 lung colon 68 colorectal lung 68 lung pancreatic 66 ovarian breast 65 pancreatic lung 65 gastrointestinal stromal tumors 65 metastatic colorectal 64 ovarian lung 64 IgG1 monoclonal antibody 63 Sutent sunitinib 63 metastatic carcinoma 63 Taxotere docetaxel 63 pancreatic colon 63 Bayer Nexavar 63 breast pancreatic 62 Vectibix panitumumab 62 nonsmall cell lung cancer 62 Nexavar ® 62 myelofibrosis polycythemia vera 62 ovarian colon 62 Fludara ® 62 skeletal metastases 62 Camptosar ® 62 kidney urologic 61 sorafenib tablets 61 lung prostate 61 pancreatic prostate 61 Bonefos 60 prostate breast 60 Nexavar sorafenib 60 superficial basal cell carcinoma 60 CYT# potent vascular disrupting 60 prostate lung 60 R sorafenib tablets 60 antiangiogenesis therapies 60 Herceptin trastuzumab 60 Erbitux cetuximab 60 Gleevec imatinib mesylate 60 ImClone Erbitux 60 carcinoma HCC 60 factor receptor EGFR 60 sarcoma melanoma 60 breast ovary 59 proteasome inhibitor 59 Basal cell 59 erlotinib Tarceva ® 59 gefitinib Iressa 59 colon pancreas 59 HER2 receptor 59 ixabepilone 59 Cladribine 59 Merck KGaA Erbitux 59 relapsed leukemia 59 epithelial tumors 59 Peginterferon alfa 2b 59 colorectal ovarian 59 papillary renal cell carcinoma 59 Onco TCS 59 Novartis Gleevec 59 androgen receptor AR 59 ZADAXIN ® 59 Velcade bortezomib 59 docetaxel Taxotere 59 Squamous cell 59 paclitaxel Taxol 59 esophagus colon 59 IAP inhibitor 59 tumor xenograft models 59 myelomas 59 vinca alkaloids 59 Kit CD# positive 59 bladder ovarian 59 Mabthera 58 sunitinib Sutent 58 Rituxan rituximab 58 cetuximab Erbitux 58 Everolimus 58 neuroendocrine cancers 58 colorectal breast 58 prostate colon 58 trastuzumab DM1 58 cetuximab Erbitux R 58 docetaxel Taxotere ® 58 Zolinza 58 taxane chemotherapy 58 Neulasta ® 58 Avastin bevacizumab 58 immunological diseases 58 pediatric acute lymphoblastic 58 anti angiogenic agents 58 Genentech Rituxan 58 lymphomas leukemias 58 oncology indications 58 tumors GIST 58 Camptosar 58 tumor metastases 58 Amgen Vectibix 58 YONDELIS 58 Carcinoid tumors 58 essential thrombocythemia ET 58 Campath ® 58 cisplatin resistant 58 tyrosine kinase inhibitors TKIs 58 metastatic HER2 positive 58 breast ovarian 58 Papillary 58 Ixempra 58 Pegintron 58 Vandetanib 58 colorectal pancreatic 58 epithelial cancers 57 uterine ovarian 57 Genentech Herceptin 57 Tarceva erlotinib 57 PDGF receptor 57 histone deacetylase inhibitor 57 Hycamtin 57 FLT3 57 erlotinib Tarceva 57 commonly mutated genes 57 neuroendocrine tumors 57 bladder cancers 57 Sutent sunitinib malate 57 hypereosinophilic syndrome 57 Allovectin 7 57 Tykerb lapatinib 57 dasatinib Sprycel 57 Insegia 57 imatinib Gleevec ® 57 proliferative disorders 57 liposomal doxorubicin 57 receptor tyrosine kinase inhibitor 57 EGFR inhibitors 57 metastatic gastric 57 T#I mutant 57 anticancer therapy 57 prostate ovarian 57 K ras mutations 57 gastric pancreatic 57 Celgene Revlimid 57 Metastatic breast cancer 57 Ceflatonin 57 luteinizing hormone releasing 57 multiple myeloma MM 57 Nexavar tablets 57 panitumumab Vectibix 57 Irinotecan 57 Sanofi Aventis Taxotere 56 VEGF inhibitors 56 colon prostate 56 NF kB pathway 56 pancreatic bladder 56 Panzem 56 pancreatic colorectal 56 docetaxel Taxotere R 56 multi kinase inhibitor 56 Roche Xeloda 56 eflornithine 56 AstraZeneca Iressa 56 etanercept Enbrel 56 Pemetrexed 56 unresectable tumors 56 Sprycel 56 Pfizer Sutent 56 Medullary thyroid cancer 56 cutaneous T 56 Xanafide 56 fluoropyrimidine 56 tubulin inhibitor 56 Exelixis compounds 56 castration resistant 56 demonstrated antitumor activity 56 pancreatic ovarian 56 Treanda 56 subependymal giant cell 56 hypoxia activated prodrug 56 refractory chronic lymphocytic 56 histologies 56 paclitaxel Taxol ® 56 molecularly targeted 56 TEMODAL 56 humanised monoclonal antibody 56 novel VDA molecule 56 thalidomide Thalomid 56 Sebivo 56 MyVax 56 recurrent NSCLC 56 TREANDA 56 metastatic bladder 56 squamous non 56 hematological cancers 56 Li Fraumeni Syndrome 56 angiogenesis inhibitor 56 TELINTRA 56 Evoltra ® 56 cediranib 56 mTOR inhibitor 56 cervical breast 56 metastatic colon cancer 56 myeloproliferative disorders 56 androgen independent 56 Advexin 56 histone deacetylase HDAC inhibitor 56 trastuzumab Herceptin R 56 Acute myeloid leukemia AML 56 Satraplatin 56 prostate carcinomas 56 Romiplostim 56 cutaneous T cell 56 signal transduction inhibitor 56 anthracycline taxane 56 Paraplatin 56 Abbott Humira 56 tyrosine kinase inhibitors 55 Gemzar 55 sorafenib Nexavar 55 Chronic lymphocytic leukemia CLL 55 Amrubicin 55 AKT inhibitor 55 Novartis Afinitor 55 inhibiting tumor 55 hormone refractory prostate 55 prostate pancreatic 55 Yondelis 55 PI3K/Akt pathway inhibitor 55 gastrointestinal stromal tumors GIST 55 Vidaza ® 55 hormonal therapies 55 imatinib Gleevec 55 B CLL 55 Proxinium TM 55 Alimta pemetrexed 55 bevacizumab Avastin 55 Crizotinib 55 gemcitabine chemotherapy 55 prostate colorectal 55 Vectibix 55 pediatric malignancies 55 Gleevec imatinib 55 breast colon 55 Certican 55 ovarian pancreatic 55 metastatic cancers 55 hormone refractory metastatic prostate 55 iniparib 55 Ethyol 55 pancreatic cancers 55 peritoneal carcinomatosis 55 dasatinib Sprycel ® 55 investigational compounds 55 Votrient 55 EGFR HER2 55 TRISENOX 55 Gliadel Wafer 55 HepDirect prodrug 55 Pertuzumab 55 Sezary syndrome 55 selective kinase inhibitor 55 infusional 5-FU/LV 55 HER2 positive breast 55 gastrointestinal stromal tumor 55 Squamous 55 leukemias lymphomas 55 Panzem R NCD 55 essential thrombocythemia 55 Clevudine 55 lung carcinomas 55 BRAF inhibitor 55 squamous cell carcinoma SCC 55 sodium thiosulfate STS 55 Oxaliplatin 55 hematologic disorders 55 carcinoid tumors 55 orally administered inhibitor 55 temsirolimus 55 Docetaxel 55 vinca alkaloid 55 M2 subunit 55 Gleevec resistant 55 mycosis fungoides 55 Alessandro Riva 55 Nexavar sorafenib tablets 55 Alkeran 55 motesanib 55 ovarian colorectal 55 non squamous 55 gastric cancers 54 alkylating agents 54 ThermoDox R 54 gastrointestinal stromal tumors GISTs 54 leukemia myeloma 54 TYZEKA 54 RSR# 54 Pazopanib 54 relapsed ovarian cancer 54 Clofarabine 54 metastatic breast 54 gastrointestinal stromal tumor GIST 54 myeloproliferative diseases 54 chronic eosinophilic leukemia 54 MEK inhibitors 54 Mepact 54 metastatic GIST 54 Atrasentan 54 Epratuzumab 54 tyrosine kinase inhibitor 54 Gleevec Glivec 54 BCG refractory 54 myelodysplastic syndromes 54 Eribulin 54 trastuzumab Herceptin 54 Hycamtin ® 54 oligodendrogliomas 54 lobular carcinoma 54 bevacizumab Avastin ® 54 interferon gamma 1b 54 cetuximab Erbitux ® 54 Removab 54 Xgeva 54 squamous cell 54 Onconase 54 proteasome inhibitors 54 thymalfasin 54 Leukine 54 Fodosine 54 commercialize deforolimus 54 Vidaza azacitidine 54 Taxotere ® 54 BAY #-# 54 Abiraterone acetate 54 solid tumors 54 Daclizumab 54 Eloxatin ® 54 serous ovarian cancer 54 prostate cancer mCRPC 54 PI3K Akt 54 nilotinib Tasigna ® 54 trabectedin 54 KRAS mutant 54 Caelyx 54 Temsirolimus 54 antibody MAb 54 poly ADP ribose polymerase 54 Enbrel etanercept 54 lung colorectal 54 advanced metastatic renal 54 anemias 54 polycythemia vera PV 54 Allovectin 7 ® 54 Gemzar ® 54 hormone gastrin 54 metastatic renal 54 metaglidasen 54 colon breast 54 refractory acute promyelocytic 54 colorectal gastric 54 Troxatyl 54 calcineurin inhibitors 54 Annamycin 54 renal carcinoma 54 Starlix 54 hematologic malignancies 54 Targretin capsules 54 postoperative pathology 54 mertansine 54 refractory metastatic colorectal cancer 54 UPLYSO 54 non resectable 54 Arzerra 54 Casodex 54 SUTENT ® 54 renal cell carcinoma 54 CDP# 54 lymphoid malignancies 54 SCCHN 54 MAGE A3 ASCI 54 Chronic lymphocytic leukemia 54 Revlimid lenalidomide 54 familial amyloidotic polyneuropathy FAP 54 RITUXAN 54 Fludarabine 54 rituximab Rituxan 54 AVASTIN 54 Tarceva TM 54 Torisel 54 Nexavar 53 bafetinib 53 adenocarcinomas 53 Fludara 53 refractory multiple myeloma 53 Phase #b/#a clinical 53 mouse xenograft models 53 EGFR tyrosine kinase inhibitors 53 Hepatocellular Carcinoma HCC 53 pancreatic carcinoma 53 squamous 53 TTR amyloidosis 53 malignancies 53 Theratope 53 acyclovir Lauriad R 53 Tekamlo 53 preclinical xenograft models 53 hematological disorders 53 pemphigus vulgaris 53 Eloxatin 53 anti EGFR antibody 53 anticancer agents 53 Fusilev 53 GW# [003] 53 oncoproteins 53 Aplidin 53 investigational monoclonal antibody 53 Taxotere R 53 HGS ETR1 mapatumumab 53 apaziquone 53 Eligard 53 OPAXIO 53 Cytoxan 53 Carboplatin 53 colon carcinoma 53 myeloproliferative neoplasms 53 cell acute lymphoblastic 53 CHOP cyclophosphamide doxorubicin vincristine 53 cell lymphomas 53 differentiated thyroid 53 sarcomatoid 53 neovascular diseases 53 non Hodgkin lymphomas 53 Gefitinib 53 PTK ZK 53 Vidofludimus 53 Zadaxin 53 advanced metastatic prostate 53 Targretin 53 Vicinium TM 53 Folotyn 53 breast carcinomas 53 breast endometrial 53 hematological diseases 53 BRCA deficient 53 fallopian tube cancers 53 prostate bladder 53 recurrent colorectal cancer 53 Acute myeloid leukemia 53 Chronic myeloid leukemia 53 cytotoxics 53 huC# DM4 53 angiogenesis inhibitors 53 pancreatic gastric 53 nonmelanoma skin cancers 53 AQ4N 53 small molecule tyrosine 53 Bayer Onyx 53 metastatic pancreatic 53 metastatic malignant 53 standard chemotherapy regimens 53 MGd 53 biliary tract cancer 53 Tasigna nilotinib 53 cell lymphoma ALCL 53 recurrent glioblastoma multiforme 53 oral deforolimus 53 Roche Avastin 53 advanced medullary thyroid 53 EGFr 53 Glioblastoma multiforme GBM 53 XL# XL# 53 Erlotinib 53 chemo resistant 53 metastatic relapsed 53 chronic viral infections 53 pancreatic islet cell 53 RNAi therapeutic targeting 53 Hodgkin lymphoma HL 53 T#I [002] 53 sPLA2 53 Bevacizumab 53 microsphere therapy 53 cancers 53 Aflibercept 53 EFAPROXYN 53 Abraxane 53 pertuzumab 53 investigational humanized monoclonal antibody 53 chemotherapeutic regimen 53 leukemia APL 53 papillary 53 ovarian endometrial 53 LHRH receptor positive 53 Pirfenidone 53 Alemtuzumab 53 Preclinical studies suggest 53 Aldara 53 lymphoproliferative disorders 53 metastatic renal cell 53 Proleukin 53 cinacalcet HCl 53 Rilutek 53 Cancidas 53 mTOR inhibitors 53 pituitary adenomas 53 ZACTIMA 53 metastatic renal cell carcinoma 53 HER2 positive metastatic breast 53 pegylated liposomal doxorubicin 53 Taxol paclitaxel 53 Arimidex anastrozole 53 Glufosfamide 53 Aurora kinase 53 Dasatinib 53 JAK inhibitors 53 myelofibrosis MF 53 mitogen activated ERK kinase 53 Eraxis 53 gene BRCA2 52 blood clot preventer 52 Canvaxin 52 trastuzumab Herceptin ® 52 prostate cancer AIPC 52 neratinib 52 Zometa zoledronic acid 52 HDACi 52 Afatinib 52 anticancer therapies 52 depsipeptide 52 Vorinostat 52 Apaziquone 52 cervical carcinoma 52 Sensipar 52 situ CIS 52 rNAPc2 52 Iressa gefitinib 52 multikinase inhibitor 52 advanced hepatocellular carcinoma 52 castrate resistant prostate cancer 52 alkylating agent 52 Panitumumab 52 ccRCC 52 myelodysplastic syndrome MDS 52 Tykerb 52 etoposide 52 metastatic lymph nodes 52 promoter hypermethylation 52 opioid induced constipation OIC 52 axitinib 52 bicalutamide 52 Roche Actemra 52 corticosteroid dexamethasone 52 investigational therapies 52 humanized monoclonal antibody 52 EGFR mutation 52 radiation sensitizer 52 mapatumumab 52 immune modulator 52 systemic anaplastic large 52 metastatic kidney 52 mRCC 52 bortezomib Velcade 52 precursor lesions 52 colorectal carcinoma 52 refractory chronic myeloid 52 refractory acute lymphoblastic 52 Teysuno 52 anaplastic 52 Clolar ® 52 Pathway Inhibitor 52 HBeAg negative 52 interferon IFN 52 Pixantrone 52 Genasense evaluating 52 Janus Kinase 52 lymphoma CTCL 52 Telintra 52 Erbitux 52 Temodar 52 Epivir 52 alpha folate receptor 52 EGFR pathway 52 Noxafil 52 PegIntron 52 Xinlay 52 Xeloda capecitabine 52 JAK inhibitor 52 systemic lupus erythematosus lupus 52 metastatic RCC 52 lung cancer NSCLC 52 cyclin dependent kinases CDKs 52 Arranon 52 Hedgehog Pathway Inhibitor 52 Gemcitabine 52 including eniluracil ADH 52 Humira adalimumab 52 MabThera Rituxan 52 PARP inhibitor 52 LHRH antagonists 52 Novartis Zometa 52 evaluating tivozanib 52 MMP inhibitors 52 lymphomas 52 HGS ETR2 52 Rebif ® 52 HDAC Inhibitor 52 ZOLINZA 52 Dapagliflozin 52 hematological malignancy 52 refractory APL 52 PNP inhibitor 52 Leukemias 52 Tavocept 52 Hsp# Inhibitor 52 advanced carcinoid 52 lobular carcinomas 52 pulmonary metastases 52 sunitinib Sutent ® 52 ATC ovarian cancer 52 cell chronic lymphocytic 52 Arixtra 52 REOLYSIN ® 52 solar keratosis 52 Hedgehog signaling pathway 52 anticancer compound 52 Zemplar 52 concurrent chemoradiation 52 unresectable locally advanced 52 IGF IR 52 cell lymphoma CTCL 52 Increlex R 52 lymphoid tumors 52 insulin analogues 52 premalignant 52 HER-2/neu 52 lymphoma Hodgkin lymphoma 52 adhesion molecule EpCAM expressing 52 neoadjuvant therapy 52 kinase inhibitors 52 prostate carcinoma 52 DAVANAT 52 basal cell carcinoma BCC 52 refractory acute myeloid 52 vorinostat 52 anticancer drugs 52 Amevive 52 Sutent 52 Chronic myeloid leukemia CML 52 Victrelis 52 EGF receptor 52 Sorafenib 52 malignant pleural mesothelioma 52 recurrent metastatic 52 Genentech Roche Chugai 52 pancreatic adenocarcinoma 52 lapatinib Tykerb 52 Ticagrelor 52 neuroendocrine carcinoma 52 Wyeth Torisel 52 sunitinib malate 52 CD# antibody [001] 52 refractory indolent non 52 IMC #B 52 pan HDAC inhibitor 52 relapsed acute myelogenous 51 endometrial ovarian 51 Orathecin 51 Femara letrozole 51 invasive lobular 51 follicular thyroid cancer 51 c MET 51 Anaplastic 51 malignant prostate 51 VEGF receptors 51 testicular cancers 51 interleukins 51 metastatic malignant melanoma 51 Genentech Roche 51 chemotherapeutic drug 51 protein kinase inhibitor 51 nonmetastatic 51 Zalbin 51 ductal carcinomas 51 reslizumab 51 gastrointestinal cancers 51 Acute myelogenous leukemia 51 Urocidin 51 humanized antibody 51 refractory metastatic 51 VEGFR2 inhibitor 51 squamous cell skin 51 Dacogen injection 51 VEGF receptor 51 Zarnestra 51 carcinomas 51 alvespimycin 51 chemopreventive agents 51 eribulin mesylate 51 Civacir 51 pancreatic neuroendocrine tumors 51 xenograft models 51 hepatocellular cancer 51 hepatocellular carcinoma HCC 51 nucleoside analog 51 anidulafungin 51 Hexvix 51 anti angiogenic therapy 51 pancreatic NET 51 Sudhir Agrawal D.Phil 51 vemurafenib 51 distant metastasis 51 non squamous NSCLC 51 Raptiva R 51 lenalidomide Revlimid R 51 T DM1 51 MALT lymphoma 51 small lymphocytic lymphoma 51 mutated KRAS gene 51 idarubicin 51 urothelial carcinoma 51 Avastin 51 Mimpara 51 Acute lymphoblastic leukemia 51 tremelimumab 51 systemic ALCL 51 factor receptor 51 AEG# 51 Mycograb 51 temozolomide Temodar 51 follicular Non Hodgkin 51 basal cell cancer 51 hamartomas 51 immunomodulating 51 EndoTAGTM 1 51 drug Erbitux 51 unresectable 51 hA# 51 taxanes 51 Revlimid 51 Follicular lymphoma 51 tumor subtypes 51 HIF 1α 51 carcinoid 51 Vfend 51 lymphoma subtypes 51 VEGF Trap 51 Malignant mesothelioma 51 MOZOBIL 51 dermatofibrosarcoma protuberans 51 Myelofibrosis 51 intestinal polyps 51 thromboembolic disease 51 Advagraf 51 colon pancreatic 51 Kynapid 51 lymphoma leukemia 51 efalizumab 51 CD# monoclonal antibody 51 cilengitide 51 Actemra 51 malignant pancreatic 51 kinase inhibitor 51 anaplastic astrocytoma 51 Campath 51 Merck Januvia 51 targeting CD# 51 goserelin 51 platinum refractory 51 Renal cell carcinoma 51 Raptiva ® 51 Cutaneous T 51 prostate adenocarcinoma 51 mutational status 51 leukemia AML 51 Loramyc 51 neoplastic cells 51 Hsp# inhibitors 51 cytotoxic 51 cervical uterine 51 Jevtana 51 refractory NSCLC 51 pro angiogenic 51 vinflunine 51 Phase #/#a trial 51 Adjuvant chemotherapy 51 lasofoxifene 51 CCR5 receptor antagonist 51 Omnitarg 51 metastatic melanomas 51 colorectum 51 malignant growths 51 metastatic carcinoid 51 malignant pheochromocytoma 51 breast colorectal 51 non hodgkin lymphoma 51 Zytiga 51 LBH# 50 neoplastic 50 Glioblastoma Multiforme 50 nonmelanoma 50 Golimumab 50 c MYC 50 epithelial ovarian 50 valopicitabine 50 TroVax ® 50 HuMax CD4 50 Akt inhibitor 50 Telavancin 50 non metastatic osteosarcoma 50 Icatibant 50 DPP4 inhibitor 50 HuLuc# 50 Alimta 50 Squamous cell carcinomas 50 carboplatin paclitaxel 50 ara C 50 docetaxel chemotherapy 50 Junovan 50 Metastatic 50 cytotoxic agents 50 metastatic neuroendocrine tumors 50 hormonally sensitive 50 Colon polyps 50 PLX# 50 Doxil 50 osteosarcomas 50 stage IIIB IV 50 Halaven 50 carcinoma mCRC 50 seminoma 50 Boceprevir 50 factor G CSF 50 FGFR2 50 pemetrexed Alimta 50 synthetic retinoid 50 lumiliximab 50 oral prodrug 50 colorectal adenocarcinoma 50 imatinib resistant 50 gemcitabine carboplatin 50 metastatic prostate 50 sodium glucose cotransporter 50 colorectal 50 lymph node enlargement 50 UCB Cimzia 50 Axitinib 50 Aclasta Reclast 50 Cimzia TM 50 Thalomid 50 blood thinner Xarelto 50 anticancer agent 50 neoplasias 50 colon cancers 50 deforolimus 50 Rituxan MabThera 50 gastric carcinoma 50 Uplyso 50 oral ridaforolimus 50 Bezielle 50 liposomal formulation 50 hematological malignancies 50 stem cells CSCs 50 EOquin 50 Rituxan 50 leukemia CLL 50 antiangiogenic 50 induce apoptosis 50 Dificid 50 glioblastoma multiforme GBM 50 molecular abnormalities 50 tesetaxel 50 PEG INTRON 50 IRX 2 50 Zactima 50 PARP inhibitors 50 Rezonic 50 Glioblastoma multiforme 50 amrubicin 50 soft tissue sarcomas 50 epithelioid 50 ovarian cancers 50 Malignant tumors 50 imatinib mesylate 50 leukemia lymphoma multiple myeloma 50 Colazal 50 posterior uveitis 50 Genasense ® 50 ridaforolimus 50 IgG1 antibody 50 chemotherapeutic agent 50 Istodax 50 Fosrenol 50 OMP #M# 50 IMC A# 50 papillary carcinoma 50 pilocytic astrocytomas 50 cirrhosis liver failure 50 Reverset 50 xanthine oxidase inhibitor 50 NovaBay Aganocide compounds 50 huN# DM1 50 ADVEXIN 50 cisplatin chemotherapy 50 malignant cancerous 50 endostatin 50 Brain metastases 50 sorafenib Nexavar ® 50 Arzerra ofatumumab 50 LEUKINE 50 HER2 positive 50 regorafenib 50 BRAF V# mutation 50 vismodegib 50 pheochromocytoma 50 liver metastasis 50 trans retinoic acid ATRA 50 NEUPOGEN 50 refractory ovarian cancer 50 CD# expressing 50 ENMD # 50 oral JAK1 50 chemotherapeutics 50 blood thinner prasugrel 50 Kepivance 50 galiximab 50 CHOP chemotherapy 50 hepatorenal syndrome 50 AA amyloidosis 50 Trastuzumab 50 syngeneic 50 PI3K inhibitors 50 SEBIVO 50 follicular lymphoma FL 50 SAR# [004] 50 monoclonal antibody therapies 50 CTAP# Capsules 50 haematopoietic 50 fenofibric acid 50 Fareston 50 colorectal cancers 50 Vertex telaprevir 50 MLL AF9 50 Omacetaxine 50 noncancerous cells 50 basiliximab 50 AEGR 50 capecitabine Xeloda R 50 paclitaxel cisplatin 50 biliary cancer 50 Tay Sachs thalassemia 50 V#F mutation 50 dacetuzumab 50 metastatic hormone refractory 50 bone metastasis 50 cladribine 50 adjuvant colon cancer 50 Acapodene 50 Seliciclib 50 TTR gene 50 cell malignancies 50 relapsed acute lymphoblastic 50 CLL SLL 50 darapladib 50 hormone receptor positive 50 GVAX 50 IGF 1R 50 fallopian tube carcinoma 50 cancer mCRC 50 L BLP# 50 Bexxar 50 Imprime PGG 49 prostate cancers 49 lymphocytic leukemia 49 Celebrex celecoxib 49 Doxil ® 49 hypoxia inducible factor 49 anti fibrotic 49 tanespimycin 49 Bortezomib 49 mitochondrial toxicity 49 zalutumumab 49 metastatic melanoma 49 HER2 positive cancers 49 systemic lupus erythematosus 49 Chronic Lymphocytic Leukemia CLL 49 haematological malignancies 49 TNF inhibitors 49 PNET 49 BRIM2 49 kinase inhibition 49 Basal Cell 49 Certriad 49 Glioma 49 cMET 49 enzastaurin 49 Avelox 49 fingolimod 49 situ LCIS 49 NSCLC 49 Telcyta 49 GISTs 49 JAK3 49 cell carcinoma